Leap Therapeutics LPTX

$ 2.89 3.96%

Quarterly report 2024-Q3
added 11-13-2024

Leap Therapeutics Balance Sheet 2011-2024 | LPTX

Annual Balance Sheet Leap Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-64.8 M	-114 M	-51.5 M	-2.86 M	-16.3 M	-25.7 M	29.5 M	-21 M	-10.9 M	-19 M	-15.3 M	-
Long Term Debt	-	262 K	37 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	262 K	416 K	432 K	408 K	474 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	348 K	711 K	3.45 M	11.9 M	70.5 M	-	-	-	3.11 M	-
Total Current Liabilities	12.7 M	11.2 M	9.99 M	7.37 M	8.49 M	6.45 M	6.08 M	-	-	-	-	-	-
Total Liabilities	12.7 M	11.5 M	10 M	7.72 M	9.2 M	9.9 M	17.9 M	6.46 M	1.28 M	2.49 M	1.97 M	4.61 M	-
Deferred Revenue	-	-	-	1.5 M	-	-	-	-	-	-	-	-	-
Retained Earnings	-400 M	-318 M	-264 M	-223 M	-195 M	-154 M	-130 M	-101 M	-89.3 M	-68.2 M	-42.7 M	-24.4 M	-
Total Assets	72.8 M	70.4 M	118 M	54.4 M	7.45 M	19.1 M	29.1 M	6.46 M	28.1 M	48.7 M	20.7 M	17.7 M	-
Cash and Cash Equivalents	70.6 M	65.5 M	115 M	52.1 M	3.89 M	16.3 M	25.7 M	-	-	-	-	-	-
Book Value	60.1 M	58.9 M	108 M	46.7 M	-1.75 M	9.18 M	11.1 M	-	26.9 M	46.2 M	18.8 M	13.1 M	-
Total Shareholders Equity	60.1 M	58.9 M	108 M	46.7 M	-1.75 M	9.18 M	11.1 M	-100 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Leap Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	39 K	154 K	-	-	38 K	152 K	262 K	369 K	474 K	-	37 K	-	-	36 K	144 K	144 K	144 K	144 K	552 K	552 K	552 K	552 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	16.1 M	15.6 M	10.6 M	12.7 M	11 M	11.8 M	10.5 M	11.5 M	12.1 M	10.9 M	7.34 M	10 M	11.3 M	8.06 M	7.43 M	7.72 M	7.72 M	7.72 M	7.72 M	9.2 M	9.2 M	9.2 M	9.2 M	9.9 M	9.9 M	9.9 M	9.9 M	17.9 M	17.9 M	17.9 M	17.9 M	36.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	375 K	750 K	1.12 M	1.5 M	1.5 M	1.5 M	1.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-452 M	-434 M	-413 M	-400 M	-387 M	-373 M	-360 M	-318 M	-306 M	-291 M	-274 M	-264 M	-253 M	-242 M	-232 M	-223 M	-223 M	-223 M	-223 M	-195 M	-195 M	-195 M	-195 M	-154 M	-154 M	-154 M	-154 M	-130 M	-130 M	-130 M	-130 M	-101 M	-101 M	-101 M	-101 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	65 M	81.4 M	58 M	72.8 M	83 M	95.9 M	107 M	70.4 M	82.2 M	94.2 M	106 M	118 M	128 M	37.9 M	45.8 M	54.4 M	54.4 M	54.4 M	54.4 M	7.45 M	7.45 M	7.45 M	7.45 M	19.1 M	19.1 M	19.1 M	19.1 M	29.1 M	29.1 M	29.1 M	29.1 M	6.46 M	6.46 M	6.46 M	6.46 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	62.8 M	78.5 M	54.9 M	70.6 M	80.7 M	91.4 M	102 M	65.5 M	78.3 M	90.9 M	103 M	115 M	125 M	35.7 M	43.5 M	52.1 M	52.1 M	52.1 M	52.1 M	3.89 M	3.89 M	3.89 M	3.89 M	16.3 M	16.3 M	16.3 M	16.3 M	25.7 M	25.7 M	25.7 M	25.7 M	793 K	793 K	793 K	793 K	405 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	49 M	65.8 M	47.4 M	60.1 M	72 M	84.1 M	96 M	58.9 M	70.1 M	83.3 M	98.6 M	108 M	117 M	29.9 M	38.4 M	46.7 M	46.7 M	46.7 M	46.7 M	-1.75 M	-1.75 M	-1.75 M	-1.75 M	9.18 M	9.18 M	9.18 M	9.18 M	11.1 M	11.1 M	11.1 M	11.1 M	-29.7 M	6.46 M	6.46 M	6.46 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	49 M	65.8 M	47.4 M	60.1 M	72 M	84.1 M	28.3 M	58.9 M	70.1 M	83.3 M	98.6 M	108 M	117 M	29.9 M	38.4 M	46.7 M	46.7 M	46.7 M	46.7 M	-1.75 M	-1.75 M	-1.75 M	-1.75 M	9.18 M	9.18 M	9.18 M	9.18 M	11.1 M	11.1 M	11.1 M	11.1 M	-100 M	-100 M	-100 M	-100 M	-70.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency